2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.08F.06 Concurrent Chemoradiotherapy Followed by Durvalumab for Elderly Patients

Pdf Summary

The study examines the efficacy and safety of consolidation therapy with durvalumab following concurrent chemoradiotherapy (cCRT) in elderly patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). Conducted across six institutions in Japan, this retrospective study included patients aged 70 and over, divided into three age groups: 70–74, 75–79, and 80 years. The primary focus was on progression-free survival (PFS), with secondary endpoints including response rates, overall survival (OS), and adverse events (AEs).<br /><br />Results indicated that the PFS and OS for patients aged 80 were not inferior to those of younger groups. The initiation rate of durvalumab after cCRT in this study was approximately 78.4%, consistent with existing data from Japan. However, the initiation and completion rates of durvalumab, as well as the number of doses, decreased with age. Pneumonitis was a more frequent cause for discontinuing durvalumab in patients aged 80 and above, underscoring the need for careful monitoring for AEs in this age group.<br /><br />Despite a tendency for older patients to discontinue durvalumab due to pneumonitis, the overall survival outcomes were comparable across all age groups studied. These findings suggest that durvalumab consolidation therapy is an effective treatment option following cCRT for LA-NSCLC in elderly patients, including those 80 years and older. However, the heightened risk of AEs, particularly pneumonitis, necessitates vigilant monitoring and management during treatment. The study highlights that although the survival benefits are consistent, the side effect profile and resulting discontinuation rates present challenges in older populations that should be carefully managed to optimize patient outcomes.

Asset Subtitle

Atsuhiko Yatani

Meta Tag

Speaker Atsuhiko Yatani

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

durvalumab

consolidation therapy

elderly patients

non-small cell lung cancer

chemoradiotherapy

progression-free survival

overall survival

adverse events

pneumonitis

Japan